A whey protein-pectin composite interfacial membrane-coated resveratrol composite emulsion, its preparation method and application

A resveratrol complex emulsion was prepared by forming a whey protein-pectin electrostatic complex at the oil-water interface using a pH-driven strategy. This solved the stability and solubility issues of resveratrol, achieving a high level of liver protection and improved bioavailability, making it suitable for functional foods.

CN123100819APending Publication Date: 2026-11-17QINGDAO UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202611436995.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-16
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

In the existing technology, resveratrol has insufficient interfacial stability and solubility, resulting in low oral bioavailability and a lack of in vivo validation. The oil phase type does not have functional synergistic effects, has weak interfacial protection, and lacks in vivo pathological model validation.

Method used

A pH-driven strategy was adopted to utilize the electrostatic complex interfacial layer formed by whey protein and pectin at the oil-water interface, and a water-in-oil composite emulsion was prepared using diglyceride oil as the oil phase. The emulsion was then formed into nanoscale emulsion by high-pressure homogenization, which improved the stability and encapsulation efficiency of resveratrol.

Benefits of technology

It significantly improves the stability and oral bioavailability of resveratrol, providing a safe and efficient solution for liver-protective functional foods. It has intelligent responsive release characteristics in the gastrointestinal tract and improves lipid metabolism, making it suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123100819A_ABST
    Figure CN123100819A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of latex preparation technology in organic chemical engineering, and relates to a whey protein-pectin composite interfacial membrane-coated resveratrol composite emulsion, its preparation method, and its application. First, whey protein is dispersed in deionized water to obtain a whey protein solution; then, pectin is dispersed in deionized water to obtain a pectin solution; next, the whey protein solution is slowly added dropwise to the pectin solution to obtain a mixed solution. The pH value of the mixed solution is adjusted to 8.0–11.0 using a pH adjuster to obtain a composite aqueous phase; then, the oil phase and the composite aqueous phase are mixed at a mass ratio of 1:2–1:4, and pre-emulsified using a high-speed shear dispersion homogenizer to form a crude emulsion; finally, the crude emulsion is transferred to a high-pressure homogenizer for homogenization to obtain the emulsion. This emulsion exhibits excellent physical stability, superior protection of active ingredients, and good bioavailability. It can effectively improve lipid metabolism and also has good liver protection effects, making it suitable for the preparation of liver-protective functional foods and drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the fields of functional lipid development, bioactive ingredient delivery carriers, and liver-protective functional foods. Specifically, it relates to a resveratrol diester peanut oil composite emulsion constructed using a pH-driven strategy with whey protein-pectin as a composite interface membrane, its preparation method, and its application in the preparation of liver-protective functional foods. Background Technology

[0002] Resveratrol (Res), a natural polyphenol, has been proven to have significant antioxidant, anti-inflammatory, and chemopreventive effects. However, Res is highly hydrophobic, has low solubility in the gastrointestinal tract, and is easily metabolized and eliminated from the human body, resulting in an oral bioavailability of typically less than 1%.

[0003] Currently, developing food-grade delivery systems is an effective way to improve the stability and solubility of Res. For example, patent CN118844622A discloses a method for preparing whey protein-based nanoparticles loaded with resveratrol and its application. The method involves adding whey protein to distilled water, magnetically stirring, and allowing it to stand to obtain a whey protein solution; adding resveratrol to the whey protein solution and stirring at room temperature in the dark to obtain a mixture; centrifuging the solution to remove a small amount of insoluble matter to obtain whey protein-based nanoparticles loaded with resveratrol; the prepared nanoparticles show changes compared to whey protein, with enhanced foaming and emulsifying properties; compared to free resveratrol, whey protein-resveratrol nanoparticles have higher antioxidant properties and stronger photostability; patent CN112891305A discloses an O / W type resveratrol nanoemulsion and its preparation method and application. The prior art solution specifically includes the following steps: (1) Oil phase preparation: Resveratrol is dissolved in anhydrous ethanol, then added to edible oil (such as olive oil), mixed evenly, and filtered to obtain the oil phase, wherein the main component of the edible oil is triglycerides; (2) Aqueous phase and emulsification: The surfactant is mixed evenly with the oil phase to obtain a mixture, and the mixture is added to an unsaturated guluronic acid aqueous solution; (3) Homogenization: O / W type resveratrol nanoemulsion is obtained by high-speed homogenization. The resveratrol nanoemulsion prepared by the prior art solution has an average particle size of 11.20±1.02nm, an encapsulation rate of 93%, and can be stably stored at 4℃ for 45 days without stratification, and has good antioxidant capacity. The above-mentioned existing technologies have the following defects: (1) The interface stabilization mechanism is simple and lacks composite interface protection: the interface membrane is a monolayer membrane, the thickness and density of the monolayer adsorption membrane are insufficient, the steric hindrance effect is limited, it is difficult to effectively resist the aggregation between droplets and Ostwald ripening, and the physical protection effect on the encapsulated active ingredients is weak; (2) The oil phase type is conventional triglyceride and lacks functional synergy: its oil phase is anhydrous ethanol or triglyceride-type edible oil (such as olive oil), conventional triglyceride oil is easily resynthesized into fat and stored in the body after being absorbed by the lymphatic pathway; (4) the efficacy verification is only at the in vitro level and lacks in vivo and specific pathological model verification: the technical effect of the existing technology is only verified to the in vitro antioxidant level, and the efficacy evaluation at the in vivo animal level cannot prove its actual biological effect after oral delivery. Summary of the Invention

[0004] The purpose of this invention is to overcome the shortcomings of existing technologies and to develop a whey protein-pectin composite interfacial membrane-coated resveratrol emulsion, its preparation method, and its applications. Employing a pH-driven strategy, whey protein and pectin form an electrostatic complex interfacial layer at the oil-water interface, and using resveratrol-rich diglyceride oil as the oil phase, a water-in-oil composite emulsion is prepared. Through the overall synergy of the above technical solutions, this invention can significantly improve the stability, encapsulation efficiency, and oral bioavailability of resveratrol, providing a safe and efficient functional food ingredient solution for dietary intervention in alcoholic liver injury.

[0005] To achieve the above objectives, the present invention provides the following technical solution:

[0006] The first aspect of this invention provides a method for preparing a resveratrol composite emulsion coated with a whey protein-pectin composite interfacial membrane, specifically comprising the following steps:

[0007] (1) Aqueous phase preparation: Disperse whey protein in deionized water and stir to fully hydrate it to obtain a whey protein solution; disperse pectin in deionized water and continue stirring until completely dissolved to obtain a pectin solution;

[0008] (2) Preparation of composite aqueous phase: The whey protein solution obtained in step (1) is slowly added dropwise to the pectin solution and stirred continuously to obtain a mixed solution. The mass ratio of whey protein to pectin is 1:0.8 to 1:1.2. The pH value of the mixed solution is adjusted to 8.0 to 11.0 using a pH adjuster and allowed to stand to reach equilibrium to obtain the composite aqueous phase.

[0009] (3) Preparation of oil phase: Resveratrol was dispersed in diglyceride oil and stirred at room temperature and in the dark until completely dissolved to obtain an oil phase containing resveratrol;

[0010] (4) Preparation of crude emulsion: The oil phase obtained in step (3) and the composite aqueous phase obtained in step (2) are mixed at a mass ratio of 1:2 to 1:4 and pre-emulsified by a high-speed shear dispersion homogenizer to form a crude emulsion with micron-sized droplets;

[0011] (5) High-pressure homogenization: The crude emulsion obtained in step (4) is transferred to a high-pressure homogenizer for homogenization to obtain an emulsion with droplets at the nanoscale.

[0012] In step (1) of this invention, the protein and polysaccharide molecules are fully extended by hydration to expose active groups. Specifically, whey protein is fully hydrated by magnetic stirring for 10 to 60 minutes, and pectin is fully dissolved in water by stirring for 6 to 12 hours.

[0013] In step (2) of this invention, whey protein and pectin form a soluble complex under electrostatic attraction through pH adjustment. The pH adjuster is a NaOH solution or an HCl solution, and the pH value of the mixed solution is preferably 9.0.

[0014] In step (4) of this invention, the oil phase is sheared into micron-sized droplets. Specifically, after the oil phase and the composite aqueous phase are mixed, they are pre-emulsified for 2 to 5 minutes using a high-speed shear dispersion homogenizer at a speed of 8,000 to 12,000 rpm to form a crude emulsion.

[0015] In step (5) of this invention, the droplets are further refined to the nanoscale and a dense interfacial film is formed by applying high pressure. Specifically, the crude emulsion is transferred to a high-pressure homogenizer and homogenized 2 to 5 times under a pressure of 40 to 80 MPa to obtain a composite emulsion.

[0016] In step (3) of this invention, the diglyceride oil is a peanut oil rich in resveratrol, which is obtained from peanut roots by ultra-high pressure-ultrasound-assisted stirring extraction process, wherein the enrichment of resveratrol is not less than 10 mg / kg.

[0017] The second aspect of the present invention provides a composite emulsion prepared by the preparation method, wherein the encapsulation rate of resveratrol in the composite emulsion is not less than 93%; and the bioavailability of resveratrol in the composite emulsion is not less than 50% after in vitro simulated digestion.

[0018] The third aspect of this invention provides the application of resveratrol composite emulsion coated with whey protein-pectin composite interfacial membrane in the preparation of liver-protective functional foods and medicines, specifically in the preparation of foods and medicines for acute alcoholic liver injury.

[0019] Compared with the prior art, the beneficial effects of this invention include:

[0020] 1. pH-driven, precise interfacial assembly for superior physical stability:

[0021] This invention innovatively employs a pH-driven strategy (precisely controlling the pH of the composite aqueous phase to 9.0), utilizing the difference in charge characteristics between whey protein and pectin at different pH levels to induce the strongest electrostatic attraction and hydrophobic interaction between the two at the oil-water interface. At pH = 9-11, WPI molecules undergo moderate conformational unfolding, exposing more hydrophobic groups, thereby accelerating their adsorption on the surface of diglyceride oil droplets; simultaneously, negatively charged pectin chains are tightly wrapped around the protein layer through electrostatic anchoring and hydrogen bonding, forming a dense and highly charged protein-polysaccharide electrostatic complex interfacial film. Therefore, the emulsion of this invention exhibits excellent anti-agglomeration, anti-stratification, and anti-flocculation capabilities during long-term storage (4°C, 14 days).

[0022] 2. Excellent protective effect of active ingredients:

[0023] The protein-polysaccharide composite interfacial membrane constructed in this invention serves as a highly efficient physical barrier, exhibiting significantly superior thickness and density compared to single-protein interfacial membranes. This composite structure effectively blocks the diffusion of oxygen, light, and pro-oxidants (such as metal ions) into the oil phase, significantly delaying the oxidative degradation of resveratrol encapsulated in the oil core. Experiments demonstrate that after 14 days of storage at 4°C in the dark, the resveratrol retention rate in the composite emulsion of this invention remains as high as 96.01%, while the retention rate of the control emulsion stabilized with a single whey protein is significantly lower than that of this invention (typically less than 90%), proving the superior protective performance of the composite interface.

[0024] 3. Responsive release and significantly improved bioavailability:

[0025] The emulsion of this invention possesses unique intelligent responsive release characteristics in the gastrointestinal tract. During the simulated gastric digestion stage (pH 1.2-2.0, containing pepsin), pectin in the composite interfacial membrane contracts due to protonation, forming a denser gel-like protective layer with proteins, effectively preventing pepsin degradation and thus protecting resveratrol from gastric acid degradation. Entering the simulated intestinal digestion stage (pH 7.0, containing pancreatic enzymes and bile salts), the interfacial membrane undergoes precise biodissociation, while diglyceride oil is rapidly hydrolyzed into monoglycerides and free fatty acids. These lipolysis products and bile salts self-assemble in situ to form mixed micelles, efficiently embedding the released resveratrol into them, forming a water-soluble carrier. Through this intelligent responsive process, the bioavailability of resveratrol in the composite emulsion of this invention is significantly improved to 55.39%, nearly 1.75 times higher than that of traditional emulsions stabilized with a single whey protein (whose bioavailability is only 31.59%). This provides an effective solution to the long-standing problem of low oral absorption efficiency of resveratrol.

[0026] 4. Improves lipid metabolism function

[0027] This invention selects peanut oil with diglycerides as the oil phase, taking advantage of its slightly high polarity, which facilitates the dissolution of resveratrol and improves lipid metabolism, to achieve a synergistic effect between the hepatoprotective activity of resveratrol and the regulatory function of diglyceride metabolism.

[0028] 5. The preparation process is controllable, the conditions are mild, and it is easy to scale up industrially:

[0029] The preparation method of this invention requires no complex equipment or extreme reaction conditions, has simple operation steps, is easy to control the pH-driven process, has good process repeatability, and is suitable for large-scale production. The parameters of each step (stirring time, homogenization pressure, number of cycles, etc.) can be flexibly adjusted according to actual production needs, exhibiting good process adaptability and providing a feasible technical solution for the industrial production of functional food ingredients.

[0030] 5. Synergistic liver-protective effect across multiple targets in vivo:

[0031] Animal experiments have shown that the composite emulsion prepared in this invention can exert liver protection effects from three aspects: lipid metabolism regulation, enhanced antioxidant defense, and inhibition of inflammatory response, and the above protective effects are dose-dependent. Attached Figure Description

[0032] Figure 1 This is a laser confocal microscope image of the emulsion involved in the present invention.

[0033] Figure 2 The fluorescence spectrum (A) and Fourier transform infrared spectrum (B) of the emulsion involved in this invention are shown.

[0034] Figure 3 The diagrams show the particle size variation (A), zeta potential variation (B), primary oxidation product content (C), and secondary oxidation product content variation (D) of the emulsion involved in this invention after 14 days of storage at 4°C.

[0035] Figure 4 This is a comparison chart of the emulsifying activity index (EAI) and emulsifying stability index (ESI) of the emulsion involved in this invention.

[0036] Figure 5 The diagram shows an in vitro simulated lipid digestion curve (free fatty acid release rate) of the emulsion involved in this invention (A) and a comparison of the bioavailability of resveratrol (B).

[0037] Figure 6 The graph shows the results of serum liver function and lipid metabolism indicators in mice in the application examples of this invention; where A is a statistical graph of liver index and body weight, and B is a bar graph of serum ALT / AST.

[0038] Figure 7 These are representative microscopic images of mouse liver tissue pathological staining in an application example of the present invention; where A is H&E staining and B is Oil Red O staining.

[0039] Figure 8 The figures show the expression of lipid metabolism-related proteins and fatty acid indicators in mouse liver in the application examples of this invention; where A is the immunoblotting electrophoresis image and grayscale analysis statistical graph of AMPK / ACC signaling pathway proteins, B is a representative micrograph of ACC1 immunohistochemistry, and C is a statistical graph of serum TC / TG reagent kit detection indicators.

[0040] Figure 9The figures show the expression of oxidative stress-related proteins in mouse liver and the results of reagent kit indicators in the application examples of this invention; where A is the immunoblot electrophoresis image and grayscale analysis statistics of CYP2E1 / NRF2 signaling pathway proteins, B is a representative microscopic image of NRF2 immunohistochemistry, and C is a statistical chart of liver MDA, CAT, and GSH reagent kit detection indicators.

[0041] Figure 10 The figures show the expression of inflammation-related proteins and inflammatory factor indicators in mouse liver in the application examples of this invention; where A is the immunoblot electrophoresis image and grayscale analysis statistical graph of TLR4 / MyD88 signaling pathway proteins, B is the representative microscopic image of TLR4 and F4 / 80 immunohistochemistry, and C is the statistical graph of liver TNF-α and IL-6 detection indicators detected by the kit.

[0042] Figure 11 The figure shows the results of 16S rRNA sequencing analysis of mouse fecal microbiota in an application example of the present invention; where A is the dilution curve, B is the bar chart of relative abundance of species at the phylum level, C is the bar chart of relative abundance of species at the genus level, D is the PCoA principal coordinate analysis chart, E is the Venn diagram of common and unique species analysis, F is the functional abundance analysis chart, G is the multidimensional functional distribution analysis chart, and H is the COG functional classification analysis chart. Detailed Implementation

[0043] The present invention will now be described in detail with reference to the embodiments and accompanying drawings.

[0044] Example 1:

[0045] The preparation method of the whey protein-pectin composite interfacial membrane-coated resveratrol composite emulsion involved in this embodiment specifically includes the following steps:

[0046] (1) Aqueous phase preparation: Whey protein (abbreviated WPI, purchased from Sigma-Aldrich, USA, purity ≥92%) was dispersed in deionized water to prepare a solution with a protein concentration of 10 mg / mL (1%, w / v). The solution was magnetically stirred for 30 minutes to ensure complete hydration, thus obtaining a whey protein solution. Pectin (abbreviated P, purchased from Sinopharm Group, degree of esterification ≥65%) was dispersed in deionized water to prepare a solution with a pectin concentration of 10 mg / mL (1%, w / v). The solution was stirred continuously overnight until completely dissolved, thus obtaining a pectin solution.

[0047] (2) Preparation of composite aqueous phase: Slowly add whey protein solution to pectin solution (whey protein to pectin mass ratio is 1:1) while stirring continuously. Use 1 M NaOH to precisely adjust the pH of the mixed solution to 9.0, let it stand for 10-30 minutes to reach equilibrium, and obtain composite aqueous phase;

[0048] (3) Preparation of oil phase: Resveratrol standard (purchased from Maclean Company, purity ≥98%) was dispersed in diglyceride peanut oil (purchased from Shandong Changshouhua) and stirred at room temperature and in the dark until completely dissolved to obtain diglyceride peanut oil with resveratrol content of 10.17 mg / kg;

[0049] (4) Crude emulsion and high-pressure homogenization: The oil phase and the composite aqueous phase are mixed at a mass ratio of 1:3 and pre-emulsified at 10,000 rpm for 3 minutes using a high-speed shear dispersion homogenizer to form a crude emulsion;

[0050] (5) The crude emulsion was then transferred to a high-pressure homogenizer and homogenized three times at a pressure of 60 MPa to obtain the composite emulsion WPI-P-Res (pH 9).

[0051] Example 2:

[0052] The preparation method of the whey protein-pectin composite interfacial membrane-coated resveratrol composite emulsion involved in this embodiment is the same as that in Example 1, except for step (2). Step (2) specifically involves: slowly dripping the whey protein solution into the pectin solution (the mass ratio of whey protein to pectin is 1:1) while continuously stirring. The pH value of the mixed solution is precisely adjusted to 7, 8, 10 and 11 respectively, and allowed to stand for 10 to 30 minutes to reach equilibrium, thus obtaining the composite aqueous phase. After steps (3) and (4), the composite emulsions WPI-P-Res (pH 7), WPI-P-Res (pH 8), WPI-P-Res (pH 10) and WPI-P-Res (pH 11) are finally obtained.

[0053] Comparative Example 1:

[0054] The preparation method of the composite emulsion involved in this comparative example is the same as that in Example 1, except that the composite aqueous phase is replaced with the following aqueous phase. The aqueous phase is prepared as follows: whey protein is dispersed in deionized water to prepare a solution with a protein concentration of 10 mg / mL. The solution is magnetically stirred for 30 minutes to ensure full hydration. The pH value is adjusted to 7.0 using 1 M NaOH (this pH is a common condition for stabilizing emulsions with whey protein alone to ensure that the protein is in its natural folded state).

[0055] The aqueous phase was mixed with peanut oil rich in resveratrol diglycerides (oil phase of Example 2) at a mass ratio of 3:1. The mixture was pre-emulsified for 3 minutes at 10,000 rpm using a high-speed shear dispersion homogenizer. Then, it was transferred to a high-pressure homogenizer and homogenized three times at a pressure of 60 MPa to obtain a single whey protein-stabilized resveratrol emulsion WPI-Res.

[0056] Test example:

[0057] Microstructure: such as Figure 1As shown, laser confocal microscopy revealed that FITC-labeled whey protein (green fluorescence) and DAPI-labeled pectin (blue fluorescence) highly overlapped at the interface of Nile Red-labeled oil droplets (red fluorescence), forming a complete composite interfacial film.

[0058] Structural characterization: The interfacial structure of the emulsion was characterized using fluorescence spectroscopy and Fourier transform infrared spectroscopy. Figure 2 A shows the intrinsic fluorescence spectrum (excitation wavelength 295 nm). The results indicate that, compared with the natural whey protein solution, the fluorescence emission peak intensity at approximately 360 nm of each emulsion sample was quenched to varying degrees, and the maximum emission wavelength (λmax) red-shifted, indicating that WPI molecules partially unfolded during emulsification, exposing hydrophobic residues such as tryptophan to a polar environment. Among them, the WPI-P-Res (pH 9) composite emulsion exhibited the greatest fluorescence quenching and the most significant red-shift, indicating that the interaction between WPI and P was strongest and the protein conformational change was most drastic under this pH condition. Figure 2 B is the Fourier transform infrared spectrum, where the amide I band of WPI (mainly derived from C=O stretching vibration) is located near 1653 cm⁻¹. After the formation of the WPI-P composite emulsion, the amide I band shifts towards higher wavenumbers, and the degree of shift gradually increases with increasing pH from 7.0 to 9.0, indicating a decrease in the α-helix structure and an increase in the β-sheet and random coil structure of the protein, suggesting that the protein molecules tend to be in an extended state. This result is corroborated by the fluorescence spectrum, jointly demonstrating that WPI and P form a dense composite interfacial film at the oil-water interface in the WPI-P-Res (pH 9) composite emulsion.

[0059] Particle size and potential were determined using a laser particle size and zeta potential analyzer, and the results are shown in Table 1. When the pH is less than 9, both whey protein (isoelectric point approximately 5.2) and pectin (pKa approximately 3.5) are negatively charged, and electrostatic repulsion is the main mechanism between them, making it difficult to form a stable protein-polysaccharide complex interfacial film. When the pH is between 9 and 11, the absolute value of the zeta potential of the composite emulsion increases, reaching more than 28 mV. The whey protein molecules undergo appropriate conformational unfolding, exposing more hydrophobic groups, and forming a dense composite interfacial film with the pectin chains through hydrogen bonding and hydrophobic interactions.

[0060] The Res content (C0) in the emulsion was determined by ultracentrifugation-UPLC, and the encapsulation efficiency was calculated, as shown in Table 1. The encapsulation efficiency was greater than 96% at pH 9-11.

[0061] Storage stability: The emulsion was stored at 4°C in the dark for 14 days to investigate its physical and chemical stability. Figure 4-5 ).

[0062] During storage, the compound emulsions WPI-P-Res (pH 7), WPI-P-Res (pH 8), WPI-P-Res (pH 9), WPI-P-Res (pH 10) and WPI-P-Res (pH 11) remained homogeneous and stable without stratification. However, WPI-P-Res showed obvious stratification after 7 days of storage.

[0063] Measure the initial Res content (C0) and the Res content after 14 days of storage (C). t Calculate the retention rate, R% = C t / C0, as shown in Table 1. The composite emulsion containing a protein-polysaccharide complex interfacial membrane showed a significantly higher resveratrol retention rate after 14 days of storage compared to emulsions containing only a protein interfacial membrane.

[0064] Figure 3 A is a particle size variation diagram. The results show that the particle size of each group of emulsions increased slightly during storage. However, the particle size growth of the composite emulsion prepared at pH 9-11 was the slowest, much smaller than that of the composite emulsion WPI-P-Res (pH 7) and the single emulsion WPI-Res. Figure 3 B is the Zeta potential change diagram. The results show that the absolute value of the Zeta potential of each group of emulsions decreased during storage. However, the composite emulsion prepared at pH 9-11 always maintained a high surface charge density, indicating that the electrostatic repulsion effect of its interfacial film remained effective. Figure 3 C represents the change in primary oxidation products (POV). Figure 3 D is a graph showing the changes in secondary oxidation products (TBARs). The results show that the POV and TBARs values ​​of the composite emulsion prepared at pH 7-11 were significantly lower than those of WPI-Res alone throughout the storage period. This indicates that the WPI-pectin composite interfacial membrane has superior antioxidant barrier properties and can effectively block the diffusion of oxygen and pro-oxidants into the oil phase, thereby delaying the oxidative degradation of resveratrol.

[0065] Figure 4 A shows the emulsification activity index (EAI) of composite emulsions prepared at different pH values. At pH=9, the EAI value is the highest, indicating that the emulsifier has the strongest emulsification ability and the formed interfacial film is the most stable. Figure 4 B shows the emulsion stability index (ESI) of emulsions prepared at different pH values. The ESI value is the highest at pH=9, indicating that the emulsion is the most stable.

[0066] In vitro digestion and bioaccessibility: Using the INFOGEST 2.0 static digestion model, the emulsion is subjected to sequential oral-gastro-intestinal digestion. The intestinal digestive fluid is collected for ultracentrifugation to separate the micellar phase, and the free fatty acid release rate FFA (in vitro simulated lipid digestion curve A) and the bioaccessibility of resveratrol (B) are calculated. The results show that compared with the single emulsion WPI-Res, the composite emulsion prepared at pH 7-11 has a lower free fatty acid release rate FFA, indicating that the WPI-pectin composite interfacial film has a stronger barrier effect on lipase, can delay the lipolysis rate of diacylglycerol oil, and enable a slower and more controllable release of resveratrol in the gastrointestinal tract; compared with the single emulsion WPI-Res, the bioaccessibility of resveratrol in the composite emulsion prepared at pH 7-11 is increased. This is because the interfacial film of the WPI-P-Res emulsion is only composed of a single layer of protein molecules, with thin thickness and low mechanical strength, which cannot effectively resist the coalescence of droplets during storage, and is also difficult to protect resveratrol from degradation by gastric acid and enzymes during gastrointestinal digestion. The prepared composite emulsion has a whey protein-pectin composite interfacial film, and is significantly superior to the single whey protein-stabilized emulsion in terms of physical stability, active ingredient encapsulation protection, and oral bioaccessibility.

[0067] Application Example: Verification of the protective effect of the composite emulsion of the present invention on acute alcoholic liver injury in mice

[0068] 1. Experimental materials and animal models:

[0069] 60 SPF-grade male C57BL / 6 mice, aged 6-8 weeks, weighing 20-22 g, were purchased from SPF (Beijing) Biotechnology Co., Ltd., with the animal production license number: SCXK (Beijing) 2019-0010. All animal experimental procedures were reviewed and approved by the Laboratory Animal Ethics Committee of Qingdao University (Approval No.: QDU-AEC-2026638), and the 3R principle was followed.

[0070] Mice were acclimatized for 1 week under standard conditions of temperature (22±2°C), humidity (55±5%) and a 12-hour light-dark cycle, and then randomly divided into 6 groups, with 10 mice in each group:

[0071] Normal control group (CON): Daily gavage of equal volume of normal saline.

[0072] Alcohol model group (ETOH): Daily gavage of 40.2% (v / v) ethanol solution (5 g ethanol / kg body weight).

[0073] Positive drug control group (SLM): Daily gavage of 40.2% (v / v) ethanol solution (5 g ethanol / kg body weight), and 1 hour later, gavage of silymarin suspension (100 mg / kg body weight).

[0074] The low-dose emulsion group (Res-L) of this invention: 40.2% (v / v) ethanol solution (5 g ethanol / kg body weight) was administered by gavage daily, followed by the compound emulsion prepared in Example 1 (1 mg / kg body weight based on resveratrol) 1 hour later.

[0075] The medium-dose group of the emulsion of the present invention (Res-M): 40.2% (v / v) ethanol solution (5 g ethanol / kg body weight) was administered by gavage daily, followed by the compound emulsion prepared in Example 1 (2 mg / kg body weight based on resveratrol) 1 hour later.

[0076] The high-dose emulsion group of this invention (Res-H): 40.2% (v / v) ethanol solution (5 g ethanol / kg body weight) was administered by gavage daily, followed by the compound emulsion prepared in Example 1 (3 mg / kg body weight based on resveratrol) 1 hour later.

[0077] The experiment lasted for a total of 15 days. The first 7 days were for acclimatization, followed by 7 days of alcohol induction and sample intervention. Samples were collected after the last intervention.

[0078] 2. Sample collection and preprocessing:

[0079] After the last intervention, all mice were fasted for 12 hours (with free access to water). They were anesthetized by intraperitoneal injection of sodium pentobarbital (50 mg / kg), and whole blood was collected after enucleation. After standing at room temperature for 30 minutes, the blood was centrifuged at 4°C and 3000 rpm for 15 minutes to separate the supernatant serum, which was then aliquoted and stored at -80°C for later use.

[0080] After blood collection, mice were euthanized by cervical dislocation. The abdominal cavity was quickly opened and the liver was removed. The liver was rinsed with pre-cooled physiological saline, dried, weighed, and the liver index (liver weight / body weight × 100%) was calculated. A tissue block from the same location in the left lobe of the liver was taken and immersed in 4% paraformaldehyde fixative for histopathological examination. The remaining liver tissue was quickly flash-frozen in liquid nitrogen and then transferred to -80°C for storage. Fresh fecal samples were collected from each group of mice before euthanasia, immediately flash-frozen in liquid nitrogen, and then transferred to -80°C for storage for intestinal flora analysis.

[0081] 3. Detection indicators and methods:

[0082] Serum liver function and lipid metabolism indicators: The activities of alanine aminotransferase (ALT) and aspartate aminotransferase (AST), as well as the levels of total cholesterol (TC) and triglycerides (TG) in serum were measured using a fully automated biochemical analyzer. Figure 8 C)

[0083] Liver histopathological examination: After fixation with 4% paraformaldehyde, liver tissue was routinely dehydrated, embedded in paraffin, and sectioned (5 μm thick). Hematoxylin-eosin (H&E) staining and Oil Red O staining were performed, and the liver tissue structure, fatty degeneration, and inflammatory cell infiltration were observed under a light microscope. Figure 7 ).

[0084] Immunohistochemistry (IHC): After dewaxing, hydration, and antigen retrieval, paraffin sections were incubated overnight at 4°C with primary antibodies ACC1, NRF2, TLR4, and F4 / 80, respectively, followed by dewaxing with the corresponding secondary antibodies and streptavidin-horseradish peroxidase complex. DAB staining and hematoxylin counterstaining were performed. After mounting, the localization and intensity of positive expression (brownish-yellow) were observed under a microscope. Figure 8 A, Figure 9 A, Figure 10 A).

[0085] Western blotting: Approximately 50 mg of frozen liver tissue was homogenized with RIPA lysis buffer containing protease and phosphatase inhibitors. The supernatant was collected by centrifugation at 12000 rpm for 15 minutes at 4°C, and protein concentration was determined using the BCA method. An equal volume of protein (30–50 μg) was subjected to SDS-PAGE electrophoresis. The protein was transferred to a PVDF membrane using the wet transfer method. After blocking with 5% skim milk, p-AMPK, AMPK, p-ACC, ACC, CYP2E1, NRF2, TLR4, MyD88, and the internal control GAPDH primary antibody were added. The membrane was incubated overnight at 4°C. After washing, HRP-labeled secondary antibody was added and incubated at room temperature for 1 hour. ECL chemiluminescence imaging was performed, and the band gray values ​​were analyzed using ImageJ software. Standardization was performed using GAPDH as the internal control. Figure 8 B Figure 9 B Figure 10 B)

[0086] Gut microbiota 16S rRNA sequencing: Total microbial DNA was extracted from fecal samples using a fecal genomic DNA extraction kit. PCR amplification was performed targeting the V3-V4 hypervariable region. After library construction, paired-end sequencing was performed on the Illumina NovaSeq 6000 platform. After quality control and assembly, OTU clustering and species annotation were performed at a 97% similarity level. Alpha diversity (Shannon index, Chao1 index), Beta diversity (PCoA analysis), and species composition difference analysis were then conducted. Figure 11 ).

[0087] 4. Experimental Results:

[0088] (1) Effects on liver function Figure 6 )

[0089] Figure 6 A shows the statistical graphs of liver index (red bars) and body weight (blue bars). The liver index in the alcohol model group was significantly increased compared to the normal control group (P < 0.05), but decreased significantly after intervention with the emulsion of this invention. Similarly, the body weight in the alcohol model group was significantly lower than the normal control group, but increased significantly after intervention with the emulsion of this invention. These results indicate that the compound emulsion of this invention can effectively improve liver function damage caused by alcohol exposure.

[0090] Figure 6 B is a bar chart showing the serum ALT / AST ratio. Compared with the normal control group, the serum ALT and AST activities in the alcohol model group mice were significantly increased (P < 0.01), indicating that the acute alcoholic liver injury model was successfully established. After intervention with the emulsion of this invention, the serum ALT and AST activities in the medium-dose and high-dose groups were significantly lower than those in the alcohol model group (P < 0.01).

[0091] (2) Improvement effect on liver tissue pathological morphology ( Figure 7 )

[0092] Figure 7 A shows a representative photomicrograph stained with H&E. The results show that in the normal control group, the liver lobule structure was clear and intact, and the hepatocyte morphology was normal. In the alcohol model group, hepatocytes were disordered, with numerous fat vacuoles of varying sizes (fatty degeneration) appearing in the cytoplasm. Some hepatocytes swelled and exhibited ballooning degeneration, and scattered necrotic foci and inflammatory cell infiltration were visible. After intervention with the emulsion of this invention, the high-dose group showed a significant reduction in fat vacuoles and ballooning degeneration in the liver tissue, a decrease in inflammatory cell infiltration, and a tendency for the liver lobule structure to recover.

[0093] Figure 7 B shows a representative photomicrograph stained with Oil Red O. The results showed a significant increase in the area and number of red lipid droplets in the liver tissue of the alcohol model group, indicating that alcohol exposure leads to the accumulation of large amounts of neutral fat within hepatocytes. After intervention with the emulsion of this invention, the area and number of red lipid droplets in the high-dose group were significantly reduced. These results indicate that the composite emulsion of this invention can effectively alleviate alcohol-induced hepatic steatosis and inflammatory damage.

[0094] (3) Regulatory effect on lipid metabolism ( Figure 8 )

[0095] Figure 8 Figure A shows the immunoblot electrophoresis image and grayscale analysis of AMPK / ACC signaling pathway proteins. The results showed that the p-AMPK / AMPK ratio and p-ACC / ACC ratio in the liver tissue of the alcohol model group were significantly lower than those in the normal control group (P < 0.01), indicating that alcohol inhibited the activation of the AMPK signaling pathway. After intervention with the emulsion of this invention, the expression levels of p-AMPK and p-ACC proteins in the high-dose group were significantly upregulated (P < 0.01).

[0096] Figure 8 Image B shows a representative immunohistochemical micrograph of ACC1. The results show that the liver tissue of the alcohol model group showed a strong positive signal (brownish-yellow), while the high-dose emulsion group of this invention showed a significant decrease in the positive signal of ACC1, indicating that the compound emulsion of this invention can effectively inhibit the expression of ACC1 protein.

[0097] Figure 8 C represents a statistical graph of serum TC / TG levels detected by the reagent kit. In the alcohol model group, TG and TC were significantly increased compared to the normal control group. After intervention with the emulsion of this invention, the liver index in the high-dose group was significantly reduced. These results indicate that the composite emulsion of this invention improves alcohol-induced lipid metabolism disorders by activating the AMPK / ACC signaling pathway and inhibiting de novo synthesis of fatty acids in the liver.

[0098] (4) Improvement effect on liver oxidative stress ( Figure 9 )

[0099] Figure 9 A shows the immunoblot electrophoresis image and grayscale analysis of proteins in the CYP2E1 / NRF2 signaling pathway. The results showed that CYP2E1 protein expression in the liver tissue of the alcohol model group was significantly upregulated compared to the normal control group (P < 0.01), and NRF2 protein expression was also significantly upregulated (P < 0.01). After intervention with the emulsion of this invention, CYP2E1 expression in the high-dose group was significantly inhibited (P < 0.01), and NRF2 expression tended to normalize (P < 0.01).

[0100] Figure 9 B shows a representative immunohistochemical micrograph of NRF2. The results show that the positive signal of NRF2 nuclear translocation in the liver tissue of the high-dose emulsion group of the present invention was significantly enhanced compared with that of the alcohol model group, indicating that the composite emulsion of the present invention can effectively promote the nuclear translocation and activation of NRF2.

[0101] Figure 9 C represents the statistical graph of liver MDA, CAT, and GSH levels detected by the reagent kits. Compared with the normal control group, the alcohol model group showed a significant increase in malondialdehyde (MDA) content in liver tissue (P < 0.001), and a significant decrease in catalase (CAT) activity and reduced glutathione (GSH) content (P < 0.01). After intervention with the emulsion of this invention, the high-dose group showed a significant decrease in MDA content (P < 0.01), and a significant recovery in CAT activity and GSH content (P < 0.01). These results indicate that the composite emulsion of this invention reduces the source of reactive oxygen species by inhibiting CYP2E1 expression, while simultaneously activating the NRF2 pathway to enhance the liver's antioxidant defense capacity.

[0102] (5) Inhibitory effect on liver inflammatory response ( Figure 10 )

[0103] Figure 10 A shows the immunoblot electrophoresis image and grayscale analysis of inflammation-related proteins (IL-6, MyD88, TNF-α). The results showed that MyD88 protein expression in the liver tissue of the alcohol model group was significantly upregulated compared to the normal control group (P < 0.01), while the protein expression levels of pro-inflammatory cytokines TNF-α and IL-6 were also significantly increased (P < 0.01). After intervention with the emulsion of this invention, the protein expression of MyD88, TNF-α, and IL-6 in the high-dose group was significantly inhibited (P < 0.01).

[0104] Figure 10 B shows representative immunohistochemical micrographs of TLR4 and F4 / 80. The results showed that the TLR4 positive signal and the area and intensity of the macrophage marker F4 / 80 positive staining were both increased in the alcohol model group, indicating that alcohol activated liver macrophages (Kupffer cells). In the high-dose group of the emulsion of this invention, the TLR4 and F4 / 80 positive signals were significantly reduced, indicating that the composite emulsion of this invention can effectively inhibit the activation of Kupffer cells.

[0105] Figure 10 C is a statistical graph of ELISA detection indicators of TNF-α, IL-6, and IFN-γ in the liver. The results showed that the levels of tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in the liver tissue of the alcohol model group were significantly higher than those in the normal control group (P < 0.01), while the level of interferon-γ (IFN-γ) was significantly lower. After intervention with the emulsion of this invention, the levels of the above three pro-inflammatory cytokines in the medium-dose and high-dose groups were significantly lower than those in the alcohol model group (P < 0.01), showing a dose-dependent effect. These results indicate that the compound emulsion of this invention reduces the production of pro-inflammatory cytokines by inhibiting the TLR4 / MyD88 signaling pathway and Kupffer cell activation, thereby alleviating alcohol-induced liver inflammation and damage.

[0106] (6) Regulatory effect on intestinal flora structure Figure 11 )

[0107] Figure 11 A is the dilution curve, showing that the sequencing depth of each sample is sufficient and the data is reliable.

[0108] Figure 11 B is a bar chart showing the relative abundance of species at the phylum level. The results showed that the relative abundance of Proteobacteria in the alcohol model group was significantly higher than that in the normal control group, while the relative abundance of Bacteroidetes was lower; in the high-dose emulsion group of this invention, the relative abundance of Proteobacteria was significantly lower, while the relative abundance of Bacteroidetes rebounded.

[0109] Figure 11 C is a bar chart showing the relative abundance of species at the genus level. The results showed that the relative abundance of beneficial bacteria such as Lactobacillus in the alcohol model group was significantly lower than that in the normal control group; the relative abundance of Lactobacillus in the high-dose emulsion group of this invention significantly increased.

[0110] Figure 11 D represents the PCoA principal coordinate analysis diagram. The results show that the gut microbiota structure points in the alcohol model group were significantly separated from those in the normal control group. In contrast, the gut microbiota structure points in the high-dose emulsion group of this invention moved closer to those in the normal control group, indicating that the composite emulsion of this invention helps restore the overall structure of the gut microbiota damaged by alcohol.

[0111] Figure 11 E is a Venn diagram for analyzing common and endemic species. Figure 11 F is the functional abundance analysis plot. Figure 11 G is a multi-dimensional functional distribution analysis diagram. Figure 11 H represents the COG functional classification analysis diagram. The results showed that the Shannon index of the gut microbiota in the alcohol model group was significantly lower than that in the normal control group (P < 0.05), indicating that alcohol exposure reduced microbiota diversity; the Shannon index in the high-dose group significantly increased compared to the alcohol model group (P < 0.05), indicating a recovery in microbiota diversity. Functional predictive analysis showed that the compound emulsion of this invention helps repair alcohol-damaged microbial metabolic pathways related to carbohydrate metabolism and energy production.

[0112] 5. Conclusion:

[0113] This embodiment demonstrates that the resveratrol-rich peanut oil diglyceride composite emulsion prepared according to the present invention exhibits significant dose-dependent protective effects in a mouse model of acute alcoholic liver injury. Its hepatoprotective mechanism is characterized by multi-target and multi-pathway synergistic effects: it inhibits hepatic fatty acid synthesis and improves lipid metabolism disorders by activating the AMPK / ACC signaling pathway; it enhances the liver's antioxidant defense capacity by inhibiting CYP2E1 and activating the NRF2 pathway; it reduces inflammatory responses by inhibiting the TLR4 / MyD88 signaling pathway; and it maintains gut-liver axis homeostasis by regulating the gut microbiota structure. These results indicate that the composite emulsion of the present invention not only possesses excellent in vitro delivery performance but also exerts substantial hepatoprotective effects in vivo, providing a complete scientific basis for the development of functional foods or dietary supplements with clear hepatoprotective activity.

Claims

1. A method for preparing a whey protein-pectin composite interfacial membrane-coated resveratrol composite emulsion, characterized in that, Specifically, the following steps are included: (1) Aqueous phase preparation: Disperse whey protein in deionized water and stir to fully hydrate it to obtain a whey protein solution; disperse pectin in deionized water and continue stirring until completely dissolved to obtain a pectin solution; (2) Preparation of composite aqueous phase: The whey protein solution obtained in step (1) is slowly added dropwise to the pectin solution and stirred continuously to obtain a mixed solution. The mass ratio of whey protein to pectin is 1:0.8 to 1:1.

2. The pH value of the mixed solution is adjusted to 8.0 to 11.0 using a pH adjuster and allowed to stand to reach equilibrium to obtain the composite aqueous phase. (3) Preparation of oil phase: Resveratrol was dispersed in diglyceride oil and stirred at room temperature and in the dark until completely dissolved to obtain an oil phase containing resveratrol; (4) Preparation of crude emulsion: The oil phase obtained in step (3) and the composite aqueous phase obtained in step (2) are mixed at a mass ratio of 1:2 to 1:4 and pre-emulsified by a high-speed shear dispersion homogenizer to form a crude emulsion with micron-sized droplets; (5) High-pressure homogenization: The crude emulsion obtained in step (4) is transferred to a high-pressure homogenizer for homogenization to obtain an emulsion with droplets at the nanoscale.

2. The method for preparing the resveratrol composite emulsion coated with a whey protein-pectin composite interfacial membrane according to claim 1, characterized in that, The pH adjuster is a NaOH solution or an HCl solution.

3. The method for preparing the resveratrol composite emulsion coated with a whey protein-pectin composite interfacial membrane according to claim 1, characterized in that, After the oil phase and the composite aqueous phase are mixed, they are pre-emulsified for 2 to 5 minutes at a speed of 8,000 to 12,000 rpm using a high-speed shear dispersion homogenizer to form a crude emulsion.

4. The method for preparing the resveratrol composite emulsion coated with a whey protein-pectin composite interfacial membrane according to claim 1, characterized in that, The crude emulsion is transferred to a high-pressure homogenizer and homogenized 2 to 5 times under a pressure of 40 to 80 MPa to obtain a composite emulsion.

5. The method for preparing the resveratrol composite emulsion coated with a whey protein-pectin composite interfacial membrane according to claim 1, characterized in that, In step (3), the diglyceride oil is a peanut oil rich in resveratrol, which is obtained from peanut roots by ultra-high pressure-ultrasound-assisted stirring extraction process, wherein the enrichment of resveratrol is not less than 10 mg / kg.

6. The composite emulsion prepared by the preparation method according to any one of claims 1-5.

7. The composite emulsion according to claim 6, characterized in that, The encapsulation rate of resveratrol in the compound emulsion is not less than 93%; after in vitro simulated digestion, the bioavailability of resveratrol in the compound emulsion is not less than 50%.

8. The use of the composite emulsion according to claim 6 in the preparation of liver-protective functional foods and medicines.

9. The use of the composite emulsion according to claim 6 in the preparation of food and medicine for acute alcoholic liver injury.

Citation Information

Patent Citations

  • O / W type resveratrol nanoemulsion as well as preparation method and application thereof

    CN112891305A

  • Preparation method and application of resveratrol-loaded whey protein-based nanoparticles

    CN118844622A